Q3 2022 BioInvent International AB Earnings Call Transcript
()-
Thank you very much and welcome, everybody, to our call, and I will jump right into the presentation.
So on slide 3, we have summarized the events during the third quarter and we have actually quite some things. So we did successfully a direct share issue of approximately SEK300 million. We added two new members to the Board, Natalie Berner of Redmile and Nanna Lüneborg from Forbion. They were elected as new Board members of BioInvent.
And then we received also an upfront payment of USD25 million from the option and license agreement with Exelixis.
Then also we pushed ahead with our clinical programs. So we have the first patient enrolled in the Phase 1/2a evaluating our second anti-Fc gamma BI-1607 for the treatment of HER2 positive solid tumors.
We also completed, as planned, the dose escalation in the Phase 1/2a trial of BI-1808, which is our first and lead antibody against TNF receptor protein and we test this in advanced malignancies.
And then also we're very happy
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |